(HealthDay): Compared to placebo, treatment with intravenous eptinezumab after a moderate to severe migraine attack reduces the time to resolution of the headache and the most annoying symptom, according to a study published in the June 15 issue of Journal of the American Medical Association.
In a phase 3 placebo-controlled randomized trial, Paul K. Winner, DO, of the Palm Beach Headache Center in West Palm Beach, Florida, and colleagues evaluated the efficacy and adverse events related to the onset of epinezinab during a migraine attack. Eptinezumab (238 participants) or placebo (242 participants) were administered intravenously within one to six hours of the onset of a moderate to severe migraine.
The researchers found that patients treated with eptinezumab achieved statistically significantly faster headache freedom from pain (median, four hours versus nine hours with placebo; risk ratio, 1.54) and absence of the most annoying symptom (median, two hours versus three hours; risk ratio, 1.75). Two hours after infusion, headache freedom was greater in the eptinezumab group (difference between groups, 11.6%; probability, 2.27), as was the absence of the most annoying symptom. difference between groups, 19.6%; probability, 2.25). Similar and significant results were seen at four hours after infusion. In addition, significantly fewer patients treated with eptinezumab used rescue medications within 24 hours (difference between groups, -28.4 percent; probability, 0.31). No serious adverse events emerging from treatment were reported.
“Feasibility of administering treatment with eptinezumab during a migraine attack and comparison with alternative treatments they remain to be established, ”the authors write.
Several authors revealed financial links with pharmaceutical companies, including Lundbeck, which manufactures eptinezumab and funded the study.
Summary / Full text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2021 HealthDay. All rights reserved.
Citation: Eptinezumab Accelerates Pain, Relieving Symptoms of Migraine Attack (2021, June 18) Retrieved June 19, 2021 at https://medicalxpress.com/news/2021-06-eptinezumab-pain- symptom-relief-migraine.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.